FYR Bio

📍 Missoula, United States👥 21 employees💰 Last funded Dec 2019
Biotechnology Research🌐 fyr.bio
Website LinkedIn
FYR is revolutionizing the ability to dynamically observe disease and treatment response to produce better biomarkers, trials, drugs and outcomes. FYR’s EV-Omics (EVO) platform leverages its proprietary technology, SPARCs, to enrich for extracellular vesicles from diseased cells and enable the deep assessment of proteins and nucleic acids from a simple blood draw. Utilizing AI-enabled multiomic insights, EVO unravels the complexity of disease mechanisms, thereby informing potential diagnostic and treatment options. The unparalleled view provided by FYR’s multiomic approach can transform personalized patient care, from screening through therapy selection and monitoring. For more, visit fyr.bio.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in FYR Bio?
FYR Bio has 1 investors on record on gritt.io.
When did FYR Bio last raise funding?
The most recent investment in FYR Bio recorded on gritt.io was in December 2019.
What industry is FYR Bio in?
FYR Bio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is FYR Bio based?
FYR Bio is headquartered in Missoula, United States.